The endocannabinoid system and the treatment of mood and anxiety disorders

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 6, 2009, Pages 451-458

  Hill, Matthew N ^a   Gorzalka, Boris B ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ANANDAMIDE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BROMAZEPAM; BUSPIRONE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; DESIPRAMINE; DIAZEPAM; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; GLUTAMIC ACID; IMIPRAMINE; NABILONE; NEUROTRANSMITTER; NORADRENALIN; PLACEBO; RIMONABANT; SEROTONIN; TARANABANT;

AMYGDALOID NUCLEUS; ANHEDONIA; ANXIETY DISORDER; BIOCHEMISTRY; DEPRESSION; DRUG ABUSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; DRUG UPTAKE; ENZYME INHIBITION; EXPERIMENTAL TEST; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MOOD DISORDER; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; OBESITY; POSTTRAUMATIC STRESS DISORDER; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; SUICIDAL IDEATION; TRANQUILIZING ACTIVITY; TRANSGENIC MOUSE;

ANIMALS; ANXIETY DISORDERS; ENDOCANNABINOIDS; HUMANS; MOOD DISORDERS; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION;

EID: 75849127602     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709789824624     Document Type: Review

References (142)

1. Howlett, A.C. The cannabinoid receptor. Prostaglandins Other Lipid Mediat., 2002, 68-69, 619-631.
2. Herkenham, M.; Lynn, A.B.; Johnson, M.R.; Melvin, L.S.; de Costa, B.R.; Rice, K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci., 1991, 11, 563-583.
3. Moldrich, G.; Wenger, T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides, 2000, 21, 1735-1742.
4. Tsou, K.; Brown, S.; Sanudo-Pena, M.C.; Mackie, K.; Walker, J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience, 1998, 83, 393-411.
5. Hillard, C.J. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat., 2000, 61, 3-18.
6. Cota, D.; Marsicano, G.; Tschop, M.; Grubler, Y.; Flachskamm, C.; Schubert, M.; Auer, D.; Yassouridis, A.; Thone-Reineke, C.; Ortmann, S.; Tomassoni, F.; Cervino, C.; Nisoli, E.; Linthorst, A.C.; Pasquali, R.; Lutz, B.; Stalla, G.K.; Pagotto, U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest., 2003, 112, 423-431.
7. Parolaro, D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci., 1999, 65, 637-644.
8. Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365, 61-65.
9. Benito, C.; Tolon, R.M.; Pazos, M.R.; Nunez, E.; Castillo, A.I.; Romero, J. Cannabinoid CB2 receptors in human brain inflammation. Br. J. Pharmacol., 2008, 153, 277-285.
10. Gong, J.P.; Onaivi, E.S.; Ishiguro, H.; Liu, Q.R.; Tagliaferro, P.A.; Brusco, A.; Uhl, G.R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res., 2006, 1071, 10-23.
11. Van Sickle, M.D.; Duncan, M.; Kingsley, P.J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J.S.; Marnett, L.J.; Di Marzo, V.; Pittman, Q.J.; Patel, K.D.; Sharkey, K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 2005, 310, 329-332.
12. Palazuelos, J.; Aguado, T.; Egia, A.; Mechoulam, R.; Guzman, M.; Galve-Roperh, I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J., 2006, 20, 2405-2407.
13. Freund, T.F.; Katona, I.; Piomelli, D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev., 2003, 83, 1017-1066.
14. Schlicker, E.; Kathmann, M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci., 2001, 22, 565-572.
15. Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, 258, 1946-1949.
16. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun., 1995, 215, 89-97.
17. Sugiura, T.; Waku, K. Cannabinoid receptors and their endogenous ligands. J. Biochem., 2002, 132, 7-12.
18. Liu, J.; Wang, L.; Harvey-White, J.; Osei-Hyiaman, D.; Razdan, R.; Gong, Q.; Chan, A.C.; Zhou, Z.; Huang, B.X.; Kim, H.Y.; Kunos, G. A biosynthetic pathway for anandamide. Proc. Natl. Acad. Sci. USA, 2006, 103, 13345-13350.
19. Okamoto, Y.; Morishita, J.; Tsuboi, K.; Tonai, T.; Ueda, N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem., 2004, 279, 5298-5305.
20. Simon, G.M.; Cravatt, B.F. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J. Biol. Chem., 2006, 281, 26465-26472.
21. Ahn, K.; McKinney, M.K.; Cravatt, B.F. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem. Rev., 2008, 108, 1687-1707.
22. Bisogno, T. Endogenous cannabinoids: structure and metabolism. J. Neuroendocrinol., 2008, 20(Suppl 1), 1-9.
23. Ohno-Shosaku, T.; Maejima, T.; Kano, M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron, 2001, 29, 729-738.
24. Wilson, R.I.; Kunos, G.; Nicoll, R.A. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron, 2001, 31, 453-462.
25. Deutsch, D.G.; Ueda, N.; Yamamoto, S. The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot. Essent. Fatty Acids, 2002, 66, 201-210.
26. Ueda, N. Endocannabinoid hydrolases. Prostaglandins Other Lipid Mediat., 2002, 68-69, 521-534.
27. Dinh, T.P.; Carpenter, D.; Leslie, F.M.; Freund, T.F.; Katona, I.; Sensi, S.L.; Kathuria, S.; Piomelli, D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA, 2002, 99, 10819-10824.
28. Hill, M.N.; Barr, A.M.; Ho, W.S.; Carrier, E.J.; Gorzalka, B.B.; Hillard, C.J. Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity. J. Neurochem., 2007, 103, 47-56.
29. Bisogno, T.; Berrendero, F.; Ambrosino, G.; Cebeira, M.; Ramos, J.A.; Fernandez-Ruiz, J.J.; Di Marzo, V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun., 1999, 256, 377-380.
30. Ferraro, L.; Tomasini, M.C.; Gessa, G.L.; Bebe, B.W.; Tanganelli, S.; Antonelli, T. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb. Cortex, 2001, 11, 728-733.
31. Tzavara, E.T.; Davis, R.J.; Perry, K.W.; Li, X.; Salhoff, C.; Bymaster, F.P.; Witkin, J.M.; Nomikos, G.G. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol., 2003, 138, 544-553.
32. Oropeza, V.C.; Page, M.E.; Van Bockstaele, E.J. Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res., 2005, 1046, 45-54.
33. Domenici, M.R.; Azad, S.C.; Marsicano, G.; Schierloh, A.; Wotjak, C.T.; Dodt, H.U.; Zieglgansberger, W.; Lutz, B.; Rammes, G. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J. Neurosci., 2006, 26, 5794-5799.
34. Azad, S.C.; Eder, M.; Marsicano, G.; Lutz, B.; Zieglgansberger, W.; Rammes, G. Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn. Mem., 2003, 10, 116-128.
35. Di, S.; Malcher-Lopes, R.; Halmos, K.C.; Tasker, J.G. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J. Neurosci., 2003, 23, 4850-4857.
36. Sabatier, N.; Leng, G. Presynaptic actions of endocannabinoids mediate alpha-MSH-induced inhibition of oxytocin cells. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2006, 290, R577-R584.
37. Gorzalka, B.B.; Hill, M.N.; Hillard, C.J. Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci. Biobehav. Rev., 2008, 32, 1152-1160.
38. Steiner, M.A.; Wanisch, K.; Monory, K.; Marsicano, G.; Borroni, E.; Bachli, H.; Holsboer, F.; Lutz, B.; Wotjak, C.T. Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenomics J., 2008, 8, 196-208.
39. Aso, E.; Ozaita, A.; Valdizan, E.M.; Ledent, C.; Pazos, A.; Maldonado, R.; Valverde, O. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J. Neurochem., 2008, 105, 565-572.
40. Martin, M.; Ledent, C.; Parmentier, M.; Maldonado, R.; Valverde, O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl.), 2002, 159, 379-387.
41. Hill, M.N.; Gorzalka, B.B. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav. Pharmacol., 2005, 16, 333-352.
42. Berrendero, F.; Castane, A.; Ledent, C.; Parmentier, M.; Maldonado, R.; Valverde, O. Increase of morphine withdrawal in mice lacking A2a receptors and no changes in CB1/A2a double knockout mice. Eur. J. Neurosci., 2003, 17, 315-324.
43. Haller, J.; Varga, B.; Ledent, C.; Freund, T.F. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav. Pharmacol., 2004, 15, 299-304.
44. Haller, J.; Bakos, N.; Szirmay, M.; Ledent, C.; Freund, T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J. Neurosci., 2002, 16, 1395-1398.
45. Haller, J.; Varga, B.; Ledent, C.; Barna, I.; Freund, T.F. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur. J. Neurosci., 2004, 19, 1906-1912.
46. Maccarrone, M.; Valverde, O.; Barbaccia, M.L.; Castane, A.; Maldonado, R.; Ledent, C.; Parmentier, M.; Finazzi-Agro, A. Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur. J. Neurosci., 2002, 15, 1178-1186.
47. Uriguen, L.; Perez-Rial, S.; Ledent, C.; Palomo, T.; Manzanares, J. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology, 2004, 46, 966-973.
48. Varvel, S.A.; Anum, E.A.; Lichtman, A.H. Disruption of CB(1) receptor signaling impairs extinction of spatial memory in mice. Psychopharmacology (Berl.), 2005, 179, 863-872.
49. Marsicano, G.; Wotjak, C.T.; Azad, S.C.; Bisogno, T.; Rammes, G.; Cascio, M.G.; Hermann, H.; Tang, J.; Hofmann, C.; Zieglgansberger, W.; Di Marzo, V.; Lutz, B. The endogenous cannabinoid system controls extinction of aversive memories. Nature, 2002, 418, 530-534.
50. Cannich, A.; Wotjak, C.T.; Kamprath, K.; Hermann, H.; Lutz, B.; Marsicano, G. CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice. Learn. Mem., 2004, 11, 625-632.
51. Bura, S.A.; Castane, A.; Ledent, C.; Valverde, O.; Maldonado, R. Genetic and pharmacological approaches to evaluate the interaction between the cannabinoid and cholinergic systems in cognitive processes. Br. J. Pharmacol., 2007, 150, 758-765.
52. Harloe, J.P.; Thorpe, A.J.; Lichtman, A.H. Differential endocannabinoid regulation of extinction in appetitive and aversive Barnes maze tasks. Learn. Mem., 2008, 15, 806-809.
53. Holter, S.M.; Kallnik, M.; Wurst, W.; Marsicano, G.; Lutz, B.; Wotjak, C.T. Cannabinoid CB1 receptor is dispensable for memory extinction in an appetitively-motivated learning task. Eur. J. Pharmacol., 2005, 510, 69-74.
54. Kamprath, K.; Marsicano, G.; Tang, J.; Monory, K.; Bisogno, T.; Di Marzo, V.; Lutz, B.; Wotjak, C.T. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J. Neurosci., 2006, 26, 6677-6686.
55. Navarro, M.; Hernandez, E.; Munoz, R.M.; del Arco, I.; Villanua, M.A.; Carrera, M.R.; Rodriguez de Fonseca, F. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport, 1997, 8, 491-496.
56. Moreira, F.A.; Kaiser, N.; Monory, K.; Lutz, B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology, 2008, 54, 141-150.
57. Gobbi, G.; Bambico, F.R.; Mangieri, R.; Bortolato, M.; Campolongo, P.; Solinas, M.; Cassano, T.; Morgese, M.G.; Debonnel, G.; Duranti, A.; Tontini, A.; Tarzia, G.; Mor, M.; Trezza, V.; Goldberg, S.R.; Cuomo, V.; Piomelli, D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. USA, 2005, 102, 18620-18625.
58. Griebel, G.; Stemmelin, J.; Scatton, B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry, 2005, 57, 261-267.
59. Steiner, M.A.; Marsicano, G.; Nestler, E.J.; Holsboer, F.; Lutz, B.; Wotjak, C.T. Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology, 2008, 33, 54-67.
60. Hill, M.N.; Gorzalka, B.B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur. Neuropsychopharmacol., 2005, 15, 593-599.
61. Bambico, F.R.; Katz, N.; Debonnel, G.; Gobbi, G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J. Neurosci., 2007, 27, 11700-11711.
62. Rutkowska, M.; Jamontt, J.; Gliniak, H. Effects of cannabinoids on the anxiety-like response in mice. Pharmacol. Rep., 2006, 58, 200-206.
63. Patel, S.; Hillard, C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J. Pharmacol. Exp. Ther., 2006, 318, 304-311.
64. Shearman, L.P.; Rosko, K.M.; Fleischer, R.; Wang, J.; Xu, S.; Tong, X.S.; Rocha, B.A. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav. Pharmacol., 2003, 14, 573-582.
65. Rodgers, R.J.; Haller, J.; Halasz, J.; Mikics, E. 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur. J. Neurosci., 2003, 17, 1279-1286.
66. Thiemann, G.; Watt, C.A.; Ledent, C.; Molleman, A.; Hasenohrl, R.U. Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain. Behav. Brain Res., 2009, 200, 60-67.
67. Christensen, R.; Kristensen, P.K.; Bartels, E.M.; Bliddal, H.; Astrup, A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet, 2007, 370, 1706-1713.
68. Nissen, S.E.; Nicholls, S.J.; Wolski, K.; Rodes-Cabau, J.; Cannon, C.P.; Deanfield, J.E.; Despres, J.P.; Kastelein, J.J.; Steinhubl, S.R.; Kapadia, S.; Yasin, M.; Ruzyllo, W.; Gaudin, C.; Job, B.; Hu, B.; Bhatt, D.L.; Lincoff, A.M.; Tuzcu, E.M. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA, 2008, 299, 1547-1560.
69. Carr, R.D.; Gantz, I.; Erondu, N.; Moreno, M.; Suryawanshi, S.; Musser, B.; Nayee, J.; Johnson-Levonas, A.O.; Heymsfield, S.; Amatruda, A. A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results. Atheroscler. Suppl., 2008, 9, 12-16.
70. Hill, M.N.; Miller, G.E.; Ho, W.S.; Gorzalka, B.B.; Hillard, C.J. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry, 2008, 41, 48-53.
71. Hill, M.N.; Miller, G.E.; Carrier, E.J.; Gorzalka, B.B.; Hillard, C.J. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Psychoneuroendocrinology, 2008, 41(2), 48-53.
72. Hill, M.N.; Gorzalka, B.B. Impairments in endocannabinoid signaling and depressive illness. JAMA, 2009, 301, 1165-1166.
73. Denson, T.F.; Earleywine, M. Decreased depression in marijuana users. Addict. Behav., 2006, 31, 738-742.
74. Gruber, A.J.; Pope, H.G.; Jr.; Brown, M.E. Do patients use marijuana as an antidepressant? Depression, 1996, 4, 77-80.
75. Rutkowska, M.; Jachimczuk, O. Antidepressant-like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors. Acta Pol. Pharm., 2004, 61, 165-167.
76. Adamczyk, P.; Golda, A.; McCreary, A.C.; Filip, M.; Przegalinski, E. Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J. Physiol. Pharmacol., 2008, 59, 217-228.
77. Jiang, W.; Zhang, Y.; Xiao, L.; Van Cleemput, J.; Ji, S.P.; Bai, G.; Zhang, X. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J. Clin. Invest., 2005, 115, 3104-3116.
78. Morrish, A.C.; Hill, M.N.; Riebe, C.J.; Gorzalka, B.B. Protracted cannabinoid administration elicits antidepressant behavioral responses in rats: role of gender and noradrenergic transmission. Physiol. Behav., 2009, 98(1-2), 118-124.
79. McLaughlin, R.J.; Hill, M.N.; Morrish, A.C.; Gorzalka, B.B. Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect. Behav. Pharmacol., 2007, 18, 431-438.
80. Hill, M.N.; Karacabeyli, E.S.; Gorzalka, B.B. Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect. Psychoneuroendocrinology, 2007, 32, 350-357.
81. Naidu, P.S.; Varvel, S.A.; Ahn, K.; Cravatt, B.F.; Martin, B.R.; Lichtman, A.H. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl.), 2007, 192, 61-70.
82. Bortolato, M.; Mangieri, R.A.; Fu, J.; Kim, J.H.; Arguello, O.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; Piomelli, D. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol. Psychiatry, 2007, 62, 1103-1110.
83. Rademacher, D.J.; Hillard, C.J. Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31, 633-641.
84. Cravatt, B.F.; Demarest, K.; Patricelli, M.P.; Bracey, M.H.; Giang, D.K.; Martin, B.R.; Lichtman, A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA, 2001, 98, 9371-9376.
85. Bambico, F.R.; Nguyen, N.-T.; Katz, N.; Macheda, T.; Morgese, M.; Cuomo, V.; Piomelli, D.; Gobbi, G.; Emotional Behavior and Serotonergic Neurotransmission in Fatty Acid Amide Hydrolase (FAAH) Knock-Out Mice. 3-7 November 2007, 37th Annual Meeting, Society for Neuroscience, San Diego, California USA; 2007.
86. Berton, O.; Nestler, E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci., 2006, 7, 137-151.
87. Palazzo, E.; de Novellis, V.; Petrosino, S.; Marabese, I.; Vita, D.; Giordano, C.; Di Marzo, V.; Mangoni, G.S.; Rossi, F.; Maione, S. Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. Eur. J. Neurosci., 2006, 24, 2011-2020.
88. Muntoni, A.L.; Pillolla, G.; Melis, M.; Perra, S.; Gessa, G.L.; Pistis, M. Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. Eur. J. Neurosci., 2006, 23, 2385-2394.
89. Patel, S.; Roelke, C.T.; Rademacher, D.J.; Cullinan, W.E.; Hillard, C.J. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology, 2004, 145, 5431-5438.
90. Derkinderen, P.; Valjent, E.; Toutant, M.; Corvol, J.C.; Enslen, H.; Ledent, C.; Trzaskos, J.; Caboche, J.; Girault, J.A. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J. Neurosci., 2003, 23, 2371-2382.
91. Aguado, T.; Monory, K.; Palazuelos, J.; Stella, N.; Cravatt, B.; Lutz, B.; Marsicano, G.; Kokaia, Z.; Guzman, M.; Galve-Roperh, I. The endocannabinoid system drives neural progenitor proliferation. FASEB J., 2005, 19, 1704-1706.
92. Hill, M.N.; Ho, W.S.; Sinopoli, K.J.; Viau, V.; Hillard, C.J.; Gorzalka, B.B. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology, 2006, 31, 2591-2599.
93. Hill, M.N.; Carrier, E.J.; McLaughlin, R.J.; Morrish, A.C.; Meier, S.E.; Hillard, C.J.; Gorzalka, B.B. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J. Neurochem., 2008, 106, 2322-2336.
94. Chen, C.; Bazan, N.G. Lipid signaling: sleep, synaptic plasticity, and neuroprotection. Prostaglandins Other Lipid Mediat., 2005, 77, 65-76.
95. Hill, M.N.; Titterness, A.K.; Morrish, A.C.; Carrier, E.J.; Lee, T.T.; Gil-Mohapel, J.; Gorzalka, B.B.; Hillard, C.J.; Christie, B.R. Endogenous cannabinoid signaling is required for voluntary exercise-induced enhancement of progenitor cell proliferation in the hippocampus. Hippocampus, 2009, [Epub ahead of print].
96. Sethi, B.B.; Trivedi, J.K.; Kumar, P.; Gulati, A.; Agarwal, A.K.; Sethi, N. Antianxiety effect of cannabis: involvement of central benzodiazepine receptors. Biol. Psychiatry, 1986, 21, 3-10.
97. Phan, K.L.; Angstadt, M.; Golden, J.; Onyewuenyi, I.; Popovska, A.; de Wit, H. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J. Neurosci., 2008, 28, 2313-2319.
98. Thomas, H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend., 1996, 42, 201-207.
99. Szuster, R.R.; Pontius, E.B.; Campos, P.E. Marijuana sensitivity and panic anxiety. J. Clin. Psychiatry, 1988, 49, 427-429.
100. Navarro, M.; Fernandez-Ruiz, J.J.; de Miguel, R.; Hernandez, M.L.; Cebeira, M.; Ramos, J.A. An acute dose of delta 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. Behav. Brain Res., 1993, 57, 37-46.
101. Hill, M.N.; Gorzalka, B.B. Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. Eur. J. Pharmacol., 2004, 499, 291-295.
102. Onaivi, E.S.; Green, M.R.; Martin, B.R. Pharmacological characterization of cannabinoids in the elevated plus maze. J. Pharmacol. Exp. Ther., 1990, 253, 1002-1009.
103. Arevalo, C.; de Miguel, R.; Hernandez-Tristan, R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol. Biochem. Behav., 2001, 70, 123-131.
104. Marin, S.; Marco, E.; Biscaia, M.; Fernandez, B.; Rubio, M.; Guaza, C.; Schmidhammer, H.; Viveros, M.P. Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol. Biochem. Behav., 2003, 74, 649-656.
105. Caberlotto, L.; Rimondini, R.; Hansson, A.; Eriksson, S.; Heilig, M. Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift? Neuropsychopharmacology, 2004, 29, 15-22.
106. Genn, R.F.; Tucci, S.; Marco, E.M.; Viveros, M.P.; File, S.E. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacol. Biochem. Behav., 2004, 77, 567-573.
107. Marco, E.M.; Perez-Alvarez, L.; Borcel, E.; Rubio, M.; Guaza, C.; Ambrosio, E.; File, S.E.; Viveros, M.P. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav. Pharmacol., 2004, 15, 21-27.
108. Celerier, E.; Ahdepil, T.; Wikander, H.; Berrendero, F.; Nyberg, F.; Maldonado, R. Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence. Neuropharmacology, 2006, 50, 788-806.
109. Haller, J.; Matyas, F.; Soproni, K.; Varga, B.; Barsy, B.; Nemeth, B.; Mikics, E.; Freund, T.F.; Hajos, N. Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur. J. Neurosci., 2007, 25, 2445-2456.
110. Schramm-Sapyta, N.L.; Cha, Y.M.; Chaudhry, S.; Wilson, W.A.; Swartzwelder, H.S.; Kuhn, C.M. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology (Berl.), 2007, 191, 867-877.
111. Boucher, A.A.; Arnold, J.C.; Duffy, L.; Schofield, P.R.; Micheau, J.; Karl, T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology (Berl.), 2007, 192, 325-336.
112. Valjent, E.; Mitchell, J.M.; Besson, M.J.; Caboche, J.; Maldonado, R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br. J. Pharmacol., 2002, 135, 564-578.
113. Braida, D.; Limonta, V.; Malabarba, L.; Zani, A.; Sala, M. 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur. J. Pharmacol., 2007, 555, 156-163.
114. Naderi, N.; Haghparast, A.; Saber-Tehrani, A.; Rezaii, N.; Alizadeh, A.M.; Khani, A.; Motamedi, F. Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol. Biochem. Behav., 2008, 89, 64-75.
115. Rubino, T.; Guidali, C.; Vigano, D.; Realini, N.; Valenti, M.; Massi, P.; Parolaro, D. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology, 2008, 54, 151-160.
116. Rodriguez de Fonseca, F.; Rubio, P.; Menzaghi, F.; Merlo-Pich, E.; Rivier, J.; Koob, G.F.; Navarro, M. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther., 1996, 276, 56-64.
117. Berrendero, F.; Maldonado, R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl.), 2002, 163, 111-117.
118. Balerio, G.N.; Aso, E.; Maldonado, R. Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology (Berl.), 2006, 184, 504-513.
119. Lisboa, S.F.; Resstel, L.B.; Aguiar, D.C.; Guimaraes, F.S. Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. Eur. J. Pharmacol., 2008, 593, 73-78.
120. Moreira, F.A.; Aguiar, D.C.; Guimaraes, F.S. Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology, 2007, 52, 958-965.
121. Onaivi, E.S.; Chakrabarti, A.; Gwebu, E.T.; Chaudhuri, G. Neurobehavioral effects of delta 9-THC and cannabinoid (CB1) receptor gene expression in mice. Behav. Brain Res., 1995, 72, 115-125.
122. Roohbakhsh, A.; Moghaddam, A.H.; Massoudi, R.; Zarrindast, M.R. Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety like behaviours in rats using the elevated plus-maze test. Clin. Exp. Pharmacol. Physiol., 2007, 34, 223-229.
123. Kathuria, S.; Gaetani, S.; Fegley, D.; Valino, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med., 2003, 9, 76-81.
124. Bortolato, M.; Campolongo, P.; Mangieri, R.A.; Scattoni, M.L.; Frau, R.; Trezza, V.; La Rana, G.; Russo, R.; Calignano, A.; Gessa, G.L.; Cuomo, V.; Piomelli, D. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology, 2006, 31, 2652-2659.
125. Moise, A.M.; Eisenstein, S.A.; Astarita, G.; Piomelli, D.; Hohmann, A.G. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology (Berl.), 2008, 200, 333-346.
126. Scherma, M.; Medalie, J.; Fratta, W.; Vadivel, S.K.; Makriyannis, A.; Piomelli, D.; Mikics, E.; Haller, J.; Yasar, S.; Tanda, G.; Goldberg, S.R. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology, 2008, 54, 129-140.
127. Micale, V.; Cristino, L.; Tamburella, A.; Petrosino, S.; Leggio, G.M.; Drago, F.; Di Marzo, V. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology, 2009, 34, 593-606.
128. Haller, J.; Barna, I.; Barsvari, B.; Gyimesi Pelczer, K.; Yasar, S.; Panlilio, L.V.; Goldberg, S. Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl.), 2009, 204(4), 607-616.
129. Pamplona, F.A.; Prediger, R.D.; Pandolfo, P.; Takahashi, R.N. The cannabinoid receptor agonist WIN 55,212-2 facilitates the extinction of contextual fear memory and spatial memory in rats. Psychopharmacology (Berl.), 2006, 188, 641-649.
130. Chhatwal, J.P.; Davis, M.; Maguschak, K.A.; Ressler, K.J. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology, 2005, 30, 516-524.
131. Chhatwal, J.P.; Stanek-Rattiner, L.; Davis, M.; Ressler, K.J. Amygdala BDNF signaling is required for consolidation but not encoding of extinction. Nat. Neurosci., 2006, 9, 870-872.
132. Chhatwal, J.P.; Gutman, A.R.; Maguschak, K.A.; Bowser, M.E.; Yang, Y.; Davis, M.; Ressler, K.J. Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology, 2009, 34, 509-521.
133. Pamplona, F.A.; Bitencourt, R.M.; Takahashi, R.N. Short- and long-term effects of cannabinoids on the extinction of contextual fear memory in rats. Neurobiol. Learn. Mem., 2008, 90, 290-293.
134. Suzuki, A.; Josselyn, S.A.; Frankland, P.W.; Masushige, S.; Silva, A.J.; Kida, S. Memory reconsolidation and extinction have distinct temporal and biochemical signatures. J. Neurosci., 2004, 24, 4787-4795.
135. Niyuhire, F.; Varvel, S.A.; Thorpe, A.J.; Stokes, R.J.; Wiley, J.L.; Lichtman, A.H. The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific. Psychopharmacology (Berl.), 2007, 191, 223-231.
136. Reich, C.G.; Mohammadi, M.H.; Alger, B.E. Endocannabinoid modulation of fear responses: learning and state-dependent performance effects. J. Psychopharmacol., 2008, 22, 769-777.
137. de Oliveira Alvares, L.; Pasqualini Genro, B.; Diehl, F.; Molina, V.A.; Quillfeldt, J.A. Opposite action of hippocampal CB1 receptors in memory reconsolidation and extinction. Neuroscience, 2008, 154, 1648-1655.
138. Bitencourt, R.M.; Pamplona, F.A.; Takahashi, R.N. Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur. Neuropsychopharmacol., 2008, 18, 849-859.
139. Milad, M.R.; Rauch, S.L.; Pitman, R.K.; Quirk, G.J. Fear extinction in rats: implications for human brain imaging and anxiety disorders. Biol. Psychol., 2006, 73, 61-71.
140. Rauch, S.L.; Shin, L.M.; Phelps, E.A. Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research-past, present, and future. Biol. Psychiatry, 2006, 60, 376-382.
141. Fraser, G.A. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci. Ther., 2009, 15, 84-88.
142. Calhoun, P.S.; Sampson, W.S.; Bosworth, H.B.; Feldman, M.E.; Kirby, A.C.; Hertzberg, M.A.; Wampler, T.P.; Tate-Williams, F.; Moore, S.D.; Beckham, J.C. Drug use and validity of substance use self-reports in veterans seeking help for posttraumatic stress disorder. J. Consult. Clin. Psychol., 2000, 68, 923-927.